Multicenter, randomized, double-blind, placebo-controlled phase 3 study of mogamulizumab with open-label extension study in a minimum number of patients with human T-cell leukemia virus type-1-associated myelopathy

Tomoo Sato, Masahiro Nagai, Osamu Watanabe, Tatsuro Misu, Norihiro Takenouchi, Ryuichi Ohkubo, Satoshi Ishihara, Yoshio Tsuboi, Masahisa Katsuno, Masanori Nakagawa, Takuya Matsushita, Yasuhiro Aso, Eiji Matsuura, Takashi Tokashiki, Akihiro Mukaino, Hiroaki Adachi, Kaoru Nakanishi, Yusuke Yamaguchi, Saaya Yamaguchi, Yoshihisa Yamano*

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Fingerprint

Dive into the research topics of 'Multicenter, randomized, double-blind, placebo-controlled phase 3 study of mogamulizumab with open-label extension study in a minimum number of patients with human T-cell leukemia virus type-1-associated myelopathy'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science